Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
RESEARCH TOOLSreports
Holding QNRX?
Track your performance easily
QNRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.48 - $6.18
Previous Close$0.62
Volume203.19K
Average Volume (3M)2.62M
Market Cap
$3.13M
Enterprise Value$331.84K
Total Cash (Recent Filing)$2.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 05, 2025EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.08
Shares Outstanding5,049,720
10 Day Avg. Volume170,716
30 Day Avg. Volume2,622,651
Standard Deviation0.27
R-Squared0.13
Alpha-0.10
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$2.00Price Target Upside222.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Quoin Pharmaceuticals News
PremiumCompany Announcements
Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment for the Phase 3 Netherton Syndrome study is ongoing, with QRX003 potentially becoming the first FDA-approved therapy for this condition.
Financial StabilityThe cash reserves are expected to sustain operations beyond the Phase 3 readout of the Netherton Syndrome study, providing financial stability.
Research And DevelopmentA new research agreement with University College Cork aims to develop a topical Rapamycin formulation for rare diseases, without any upfront or milestone payments.
Bears Say
FinancingQuoin will eventually require a financing sometime in 2025.
Product DevelopmentA topical formulation of Rapamycin has been difficult due to its molecular size, poor solubility, and other physico-chemical properties.
Share PriceThe shares are trading near a 52-week low.
---
Ownership Overview
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $0.48 and its highest was $6.18 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Currently, no data Available
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Mar 05, 2025 which is in 104 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.03.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -$0.46.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 5,049,720 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went down -5.479%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
---
Quoin Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (222.48% Upside)
$2.00 (222.48% Upside)
Insider Transactions
Bought Shares
Worth $80.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.41%
12-Months-Change
Fundamentals
Return on Equity
-136.11%
Trailing 12-Months
Asset Growth
-24.41%
Trailing 12-Months
Company Description
Quoin Pharmaceuticals
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
---
QNRX Stock 12 Month Forecast
Average Price Target
$2.00
▲(222.48% Upside)
Technical Analysis
Best Analysts Covering QNRX
1 Year
1 Year Success Rate
0/17 ratings generated profit
1 Year Average Return
-70.48%
initiated a buy rating 14 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -70.48% per trade.
---